Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

The advent of AI is changing how drugs are developed by predicting likely outcomes without extensive testing. While drug companies seem hesitant to test-drive this tech, they'll likely eventually warm ...

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Its use of artificial intelligence made the stock a hot buy earlier this year. However, Recursion isn't generating much revenue, and its cash burn is concerning. Earlier this year, hype around the ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...